Visceral Adiposity Index, Body Fat Index and Fat Mass In Patients with Chronic Renal Failure
PDF
Cite
Share
Request
Original Article
P: 240-244
June 2020

Visceral Adiposity Index, Body Fat Index and Fat Mass In Patients with Chronic Renal Failure

Med Bull Haseki 2020;58(3):240-244
1. Şehir Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Adana, Türkiye
No information available.
No information available
Received Date: 04.11.2019
Accepted Date: 24.02.2020
Publish Date: 17.06.2020
PDF
Cite
Share
Request

ABSTRACT

Aim:

The aim of this study was to investigate the level of visceral adiposity index (VAI), body fat index and fat mass in patients with chronic renal failure (CRF).

Methods:

A total of 231 subjects were enrolled, of which 83, 64 and 84 subjects were hemodialysis patients, peritoneal dialysis patients and healthy subjects, respectively. VAI , body fat index and body fat mass were calculated in all groups. The results were compared between the groups. MedCalc 18.2.1 software program was used for statistical analysis.

Results:

In this study, we found higher levels of body fat index and body fat mass in the healthy group (p=0.016 and p=0.03, respectively). VAI was higher in patients with CRF (p<0.001).

Conclusion:

Visceral adipose tissue is a metabolically active organ and it is an independent risk factor for metabolic alterations and development of cardiovascular diseases. High level of VAI can give an idea about cardiovascular diseases in patients with CRF

References

1
Levey AS, Eckardt K, Tsukomoto Y, et. al. Definition and classification of chronic kidney disease : A position statement from Kidney Disease Improving Global Outcomes (KDIGO), Kidney Int 2005;67:2089-100.
2
Ideura T, Shimazui M, Morita H, Yoshimura A. Protein intake of more than 0.5 g/kg BW/day is not effective in suppressing the progression of chronic renal failure. Contrib Nephrol 2007;155:40-9.
3
Pupim LB, Ikizler TA. Uremic malnutrition: new insights into an old problem. Semin Dial 2003;16:224-32.
4
Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010;33:920-2.
5
Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007;120(3 Suppl 1): S12-8.
6
Chen S, Liu H, Liu X, et al. Central obesity, C-reactive protein and chronic kidney disease: a community-based cross-sectional study in southern China. Kidney Blood Press Res 2013;37:392-401.
7
Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013;93:359-404.
8
Chen YC, Lai SH, Tsai YW, Chang SS. Visceral Adiposity Index as a Predictor of Chronic Kidney Disease in a Relatively Healthy Population in Taiwan. J Ren Nutr 2018; 28:91-100.
9
Cordeiro AC, Qureshi AR, Stenvinkel P, et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2010; 25:562-8.
10
Kato A, Ishida J, Endo Y, et al. Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant 2011;26:1967-76.
11
Yajima T, Yajima K, Takahashi H, Yasuda K. The impact of abdominal fat levels on all-cause mortality risk in patients undergoing hemodialysis. Nutrients 2018;12;10.
12
Aguilera A, Selgas R, Diéz JJ, Bajo MA, Codoceo R, Alvarez V. Anorexia in end-stage renal disease: pathophysiology and treatment. Expert Opin Pharmacother 2001;2:1825-38.
13
Ramírez-Vélez R, Correa-Bautista JE, Sanders-Tordecilla A, et al. Percentage of Body Fat and Fat Mass Index as a Screening Tool for Metabolic Syndrome Prediction in Colombian University Students. Nutrients 2017;13;9.
14
Castro ACM, Bazanelli AP, Nerbass FB, Cuppari L, Kamimura MA. Waist circumference as a predictor of mortality in peritoneal dialysis patients: a follow-upstudy of 48 months. Br J Nutr 2017;117:1299-303.
15
Florens N, Calzada C, Lyasko E, Juillard L, Soulage CO. Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins. Toxins (Basel) 2016;16:8.
16
Barter P. Lipoprotein metabolism and CKD: Overview. Clin Exp Nephrol 2014;18:243-6.
17
Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008;28:1039-49.
18
Weinberg JM. Lipotoxicity. Kidney Int 2006;70:1560-6.
19
Huang J, Zhou C, Li Y, et al. Visceral adiposity index, hypertriglyceridemic waist phenotype and chronic kidney disease in a southern Chinese population: a cross sectional study. Int Urol Nephrol 2015;47:1387-96.
20
Borazan A, Binici DN. Relationship between insulin resistance and inflamation markers in hemodialysis patients. Ren Fail 2010;32:198-202.
21
Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13:1894-900.